LifeScience Emerging Biotech

X-Therma Raises $22.4 Million in Series B Funding to Revolutionize Regenerative Medicine and Extend Organ Preservation

    X-Therma Inc., an innovator in biotechnology focusing on regenerative medicine and organ preservation, announces the successful completion ...

 March 14, 2024 | News

ImmunAbs Announces Triumph in Phase 1 Clinical Trial of Novel Autoimmune Disease Therapy, IM-101

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, today announced the successful completion of th...

 March 12, 2024 | News

Aptamer Group and Unilever Strengthen Ties with Optimer® Development for Consumer Goods

  Aptamer Group plc (AIM: APTA), the developer of novel Optimer® binders to enable innovation in the life sciences industry, today...

 March 11, 2024 | News

Sunbird Bio Advances Alzheimer's Diagnosis with APEX Blood Test, Matching PET Scan Accuracy

Sunbird Bio, a biotechnology company developing proprietary protein- and blood-based technologies to improve diagnosis and treatment of neurological disord...

 March 06, 2024 | News

YolTech's Gene Editing Therapy YOLT-201 Advances to Phase I Clinical Trials for Rare Genetic Disease

YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced the Center for Drug Evaluation ...

 March 05, 2024 | News

Neomorph, Novo Nordisk Partner on Molecular Glue Degraders for Diseases

Collaboration leverages Neomorph's leading molecular glue discovery platform and Novo Nordisk's extensive expertise in cardiometabolic and rare diseases ...

 March 27, 2024 | News

Enveric Biosciences Divests Cancer-Targeting Cannabinoid IP to Focus on Mental Health Therapeutics

  Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm at the forefront of developing neuroplastogenic small-molecule therapeutics, an...

 February 26, 2024 | News

Cure Brain Cancer Foundation CEO Lance Kawaguchi Triumphs in SouthPoleTrek4Cancer, Raising Over $1 Million

     Lance Kawaguchi, the dynamic CEO of Cure Brain Cancer Foundation, has achieved an extraordinary milestone by ...

 February 26, 2024 | News

RSSL Launches Innovation Hub for Biotech Support with Labs and Services

  RSSL’s Innovation Hub will be a supportive ecosystem for early-stage biotech companies, providing a wide range of tailored services to help t...

 February 22, 2024 | News

Hox Therapeutics and Vernalis Enter Collaboration to Advance Oncology Drug Discovery

Hox Therapeutics Ltd, a pioneering biotechnology company dedicated to developing targeted cancer therapies, and Vernalis (R&D) Ltd, a renowned subsidia...

 February 22, 2024 | News

Biocytogen and Gilead Forge Landmark Collaboration to Harness Fully Human Antibody Library for Therapeutic Innovations

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a leading biotechnology company,  announced a significant coll...

 February 20, 2024 | News

AffaMed's NDA for DEXTENZA Accepted by Singapore HSA for Post-Surgery Ocular Treatment

AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products&...

 February 19, 2024 | News

PharusDx Secures Exclusive License for Breakthrough Pancreatic Cancer Biomarkers from City of Hope

  Pharus Diagnostics ("PharusDx") has announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be...

 February 16, 2024 | News

Cathay Biotech and 3P.COM Forge Groundbreaking Joint Venture to Propel Sustainable Composite Innovations

In a strategic move towards sustainable innovation, Cathay Biotech Inc. of China and 3P.COM Co. Limited of South Korea have signed a landmark joint venture...

 February 09, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close